Medical diagnosis is about to undergo a revolution based on the next generation of electrochemical sensors that employ electrochemical impedance spectroscopy (EIS).
Aureum Diagnostics is a spin-out company from the world-leading Innovation Centre at the University of Strathclyde. The Company will build on the work of Dr Damion Corrigan at Strathclyde University, to develop rapid, cheap, electrochemical sensors for the diagnosis of COVID and other life-threatening conditions including sepsis and heart attack.
The Aureum technology is a platform that can use many different approaches to detect a wide range of medically important molecules. For instance, the platform can be used to detect nucleic acid or detect protein targets with antibodies, receptors or aptamers. In addition to COVID tests, the company will develop tests for sepsis, a condition responsible for more deaths than lung, breast and colon cancer combined, and for Hodgkin’s disease, the commonest cancer of young adults.
|Product||MedTech Growth EIS|
|Sector||Sector Medical Technology|
|Aim of funding||Aim of funding Growth|
|HMRC Advanced Assurance received||In application|
|Envisaged investor exit||4-5 years|
|Targeted return||Targeted return 7 to 15 x gross investment|